Femasys (NASDAQ:FEMY) Price Target Cut to $10.00 by Analysts at Maxim Group

Femasys (NASDAQ:FEMY) had its target price dropped by analysts at Maxim Group from $30.00 to $10.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 336.68% from the stock’s current price.

A number of other research analysts have also recently commented on FEMY. Weiss Ratings raised Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Wall Street Zen upgraded Femasys to a “hold” rating in a research report on Saturday, June 13th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $56.67.

Femasys Price Performance

NASDAQ:FEMY remained flat at $2.29 during mid-day trading on Friday. 113,658 shares of the company traded hands, compared to its average volume of 63,992. The firm’s 50-day moving average is $3.67 and its 200-day moving average is $7.35. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91. The company has a market cap of $6.92 million, a P/E ratio of -0.42 and a beta of -2.08. Femasys has a 12 month low of $2.19 and a 12 month high of $22.20.

Insider Activity at Femasys

In other news, CFO Dov Elefant bought 15,625 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief financial officer directly owned 15,625 shares in the company, valued at $50,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kathy Lee-Sepsick purchased 15,625 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the acquisition, the chief executive officer directly owned 15,625 shares in the company, valued at $50,000. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 38,750 shares of company stock worth $124,000. 7.75% of the stock is owned by corporate insiders.

Institutional Trading of Femasys

Institutional investors have recently modified their holdings of the company. State Street Corp grew its stake in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares during the last quarter. Kovack Advisors Inc. bought a new position in Femasys during the 4th quarter valued at approximately $27,000. Osaic Holdings Inc. purchased a new stake in Femasys in the 2nd quarter worth approximately $45,000. HRT Financial LP purchased a new stake in Femasys in the 4th quarter worth approximately $30,000. Finally, Cetera Investment Advisers bought a new stake in shares of Femasys in the 4th quarter worth approximately $36,000. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.